MOTS-c
MOTS-c is a 16-amino-acid peptide produced by mitochondria (the energy centers of cells), encoded in mitochondrial DNA. It was the first mitochondrial peptide to enter clinical trials. Research focuses on metabolic health, exercise performance, and longevity, with natural levels declining with age.
Verified sources for MOTS-c
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of MOTS-c
Activates AMPK through the folate-AICAR pathway, improves glucose metabolism, and can translocate to the nucleus to regulate stress-response genes.
Activates AMP-activated protein kinase through the folate-AICAR pathway, serving as master metabolic regulator.
Induces metabolic adaptations similar to physical exercise, improving glucose uptake and fat oxidation in skeletal muscle.
Restores age-related muscle insulin resistance (proposed), and treatment may reverse metabolic decline.
Can move from mitochondria to nucleus during metabolic stress, directly regulating nuclear gene expression for stress response.
Circulating levels decrease with age in both humans and mice, associated with metabolic decline.
Specific polymorphism (m.1382A>C) associated with exceptional longevity in Japanese centenarians, genetic evidence for longevity role
Read Full MOTS-c Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Longevity & Cellular Health
UPDATE: FDA Picks 7 Peptides for July 2026 Reclassification Vote
The FDA will vote on reclassifying BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax for pharmacy compounding at the July 23-24 PCAC meeting.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
MOTS-c Peptide: Benefits, Mechanism, and What the Research Shows
MOTS-c is the first peptide discovered to be encoded by mitochondrial DNA. New research links it to exercise mimicry, insulin sensitivity, and cellular aging reversal.
RFK Jr. Says 14 Peptides Are Coming Back: Ban Reversal
HHS Secretary RFK Jr. told Joe Rogan that ~14 peptides banned by the FDA in 2023 will return to Category 1, restoring legal compounding access.